Drug Price Trends for NDC 70677-1153

Average Pharmacy Cost for 70677-1153

Drug Name	NDC	Price/Unit ($)	Unit	Date
FT EAR WAX REMOVAL 6.5% KIT	70677-1153-01	0.15868	ML	2026-03-18
FT EAR WAX REMOVAL 6.5% KIT	70677-1153-01	0.15856	ML	2026-02-18
FT EAR WAX REMOVAL 6.5% KIT	70677-1153-01	0.15712	ML	2026-01-21
FT EAR WAX REMOVAL 6.5% KIT	70677-1153-01	0.15705	ML	2025-12-17

Best Wholesale Price for NDC 70677-1153

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 70677-1153

Last updated: February 27, 2026

What is NDC 70677-1153?

National Drug Code (NDC) 70677-1153 corresponds to Amivantamab-vmjw (brand name: Rybrevant), a monoclonal antibody developed by Janssen Pharmaceuticals for targeted cancer therapy. It primarily treats non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.

Market Overview

Therapeutic Area and Indication

Amivantamab is approved for adult patients with metastatic NSCLC characterized by epidermal growth factor receptor (EGFR) exon 20 insertion mutations. These mutations account for approximately 4-10% of NSCLC cases globally, estimated at around 220,000 cases annually.[1]

Competitive Landscape

• Present competitors:
  • Mobocertinib (Takeda)
  • Poziotinib (Novartis)
  • Chemotherapy regimens (platinum-based combinations)
• Emerging therapies:
  • Other EGFR-targeted agents and antibody-drug conjugates in clinical trials

Market Dynamics

• Growing awareness and genetic testing increasing diagnosis rates
• Approval in multiple markets since FDA clearance in May 2021
• High unmet need in EGFR exon 20 insertion-positive NSCLC

Revenue and Sales Data

• Initial launch revenues: Estimated US$ 50-100 million in 2021[2]
• 2022 growth: Approximately 250% increase driven by expansion in indications and geographic coverage
• Projected 2023 revenues: US$ 600 million+ with annual growth rates around 40-50% for the next three years

Pricing Analysis

Current Pricing

• US Price: List price per vial approximately US$ 4,900 (based on DrugBank data [3])
• Average Treatment Cost: US$ 180,000-$220,000 per year (assuming 6-8 doses/cycle and supportive care expenses)
• Insurance Coverage: Typically covered with varying patient co-payments

Price Trends

• Oncology monoclonal antibodies maintain high list prices, with limited discounts
• Future price sensitivity depends on:
  • Competition from oral therapies (mobocertinib, poziotinib)
  • Healthcare payer negotiations
  • Patent status and market exclusivity

Regulatory and Reimbursement Environment

• Approved by FDA (May 2021), EMA approval pending
• Reimbursement primarily through Medicare and private insurers in the US
• Reimbursement rates tied to value assessments, often influenced by clinical benefit data

Market Entry and Adoption Projections

Year	Market Penetration	Sales Estimates (USD)	Key Assumptions
2023	10-15% of eligible patients	600 million - 1 billion	Uptake after expanded approvals, increased testing
2024	20-25%	1.2 - 1.8 billion	Broader insurance coverage, competitive positioning
2025	30-35%	1.8 - 2.4 billion	Full market acceptance, new indications

Risks and Opportunities

Risks:

• Entry of new oral agents reducing reliance on monoclonal antibody therapy
• Pricing pressure from payers or generics post-patent expiry
• Delays in regulatory approvals for companion diagnostics or indications

Opportunities:

• Expansion into first-line treatment settings
• Combination therapies with other targeted agents
• Growth in markets outside the US, particularly Europe and Asia

Price Projection Summary

• Short-term (2023): US$4,900 per vial, annual treatment costs US$180,000–220,000
• Mid-term (2025): Potential slight price erosion of 10-15% due to payer pressure
• Long-term (2027 onward): Possible decrease to US$4,200–4,500 per vial as competition and biosimilars emerge, depending on patent exclusivity extension or new indications

---

Key Takeaways

• NDC 70677-1153 (Rybrevant) operates in a niche but rapidly expanding NSCLC market targeting EGFR exon 20 insertion mutations.
• Revenue growth is driven by increasing diagnosis rates, expanded indications, and market adoption.
• List prices remain high; prices are likely to encounter moderation as competition intensifies.
• Sales projections forecast sustained growth through 2025, with potential plateau or decline post-2027 upon patent expiry and competitive entry.
• Market entry risks include competition and payer restrictions; opportunities exist in combination therapies and global market expansion.

---

FAQs

1. What is the primary indication for NDC 70677-1153?
   It treats metastatic NSCLC with EGFR exon 20 insertion mutations in adult patients.

2. How does the pricing of Rybrevant compare with competitors?
   It currently lists around US$ 4,900 per vial, with total treatment costs averaging US$ 180,000–220,000 annually, which is comparable to other monoclonal antibody therapies.

3. What factors influence future price projections?
   Competition from oral agents, market penetration, reimbursement policies, and biosimilar entry influence future pricing.

4. What is the expected market growth rate?
   Revenue is projected to grow around 40-50% annually through 2025, driven by increasing diagnosis and market acceptance.

5. When are biosimilar or generic versions expected?
   Likely post-2030, subject to patent protections and regulatory approvals.

---

References

1. American Cancer Society. (2022). Lung Cancer Facts & Figures. https://cancerstatisticscenter.cancer.org
2. Evaluate Pharma. (2022). Oncology Market Data. https://www.evaluategroup.com
3. DrugBank. (2023). Rybrevant. https://go.drugbank.com/drugs/DB15564